The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform

Jan Schwarz - One of the best experts on this subject based on the ideXlab platform.

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    Goals:To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children.Background:Lactobacillus species possess in vitro activity aga

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    GOALS: To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children. BACKGROUND: Lactobacillus species possess in vitro activity against H. pylori. There are no consistent data on the impact of eradication therapy supplemented with probiotics on H. pylori cure rates in childhood in vivo. STUDY: Multicenter, prospective, randomized, double-blind controlled study. Eighty-six symptomatic H. pylori-positive children were randomized either to receive the control treatment of omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days or the test treatment of omeprazole, amoxicillin, and clarithromycin for 7 days supplemented with Fermented Milk (Actimel) containing L. casei DN-114 001 (OAC-LC), for 14 days. H. pylori status was assessed at 4 weeks following therapy using two noninvasive tests. RESULTS: Intention-to-treat (ITT) based eradication rates for the OAC-LC group were 84.6% (95% CI, 71.2%-95.5%), and 91.6% (95% CI, 76.9%-98.2%) by per-protocol (PP) analysis. Eradication in the OAC group was 57.5% (95% CI, 42.2%-72.3%) in the ITT set and 61.3% (95% CI, 44.4%-75.0%) in the PP group. Eradication success was higher in the OAC-LC group compared with the OAC group in both ITT (P=0.0045) and PP analysis (P=0.0019). Primary resistance for clarithromycin could be determined in 21.2%. Side effects were infrequent. Drug compliance was good throughout the study. CONCLUSION: Supplementation with Fermented Milk, containing live special probiotic L. casei DN-114 001, confers an enhanced therapeutic benefit on H. pylori eradication in children with gastritis on triple therapy.

Yukio Yamori - One of the best experts on this subject based on the ideXlab platform.

  • effect of a γ aminobutyric acid enriched dairy Product on the blood pressure of spontaneously hypertensive and normotensive wistar kyoto rats
    British Journal of Nutrition, 2004
    Co-Authors: Kazuhito Hayakawa, Keiko Kasaha, Hiroshi Sansawa, Masayuki Kimura, Keisuke Matsumoto, Yukio Yamori
    Abstract:

    We investigated the blood-pressure-lowering effects of γ-aminobutyric acid (GABA) and a GABA-enriched Fermented Milk Product (FMG) by low-dose oral administration to spontaneously hypertensive (SHR/Izm) and normotensive Wistar–Kyoto (WKY/Izm) rats. FMG was a non-fat Fermented Milk Product produced by lactic acid bacteria, and the GABA contained in FMG was made from the protein of the Milk during fermentation. A single oral dose of GABA or FMG (5 ml/kg; 0·5 mg GABA/kg) significantly ( P >0·05) decreased the blood pressure of SHR/Izm from 4 to 8 h after administration, but did not increase that of WKY/Izm rats. The hypotensive activity of GABA was dose-dependent from 0·05 to 5·00 mg/kg in SHR/Izm. During the chronic administration of experimental diets to SHR/Izm, a significantly slower increase in blood pressure with respect to the control group was observed at 1 or 2 weeks after the start of feeding with the GABA or FMG diet respectively ( P >0·05) and this difference was maintained throughout the period of feeding. The time profile of blood-pressure change due to administration of FMG was similar to that of GABA. FMG did not inhibit angiotensin 1-converting enzyme. Furthermore, an FMG peptide-containing fraction from reverse-phase chromatography lacked a hypotensive effect in SHR/Izm rats. The present results suggest that low-dose oral GABA has a hypotensive effect in SHR/Izm and that the hypotensive effect of FMG is due to GABA.

  • Effect of a γ-aminobutyric acid-enriched dairy Product on the blood pressure of spontaneously hypertensive and normotensive Wistar–Kyoto rats
    British Journal of Nutrition, 2004
    Co-Authors: Masayuki Kimura, Keiko Kasaha, Hiroshi Sansawa, Kazuhito Hayakawa, Keisuke Matsumoto, Yukio Yamori
    Abstract:

    We investigated the blood-pressure-lowering effects of gamma-aminobutyric acid (GABA) and a GABA-enriched Fermented Milk Product (FMG) by low-dose oral administration to spontaneously hypertensive (SHR/Izm) and normotensive Wistar-Kyoto (WKY/Izm) rats. FMG was a non-fat Fermented Milk Product produced by lactic acid bacteria, and the GABA contained in FMG was made from the protein of the Milk during fermentation. A single oral dose of GABA or FMG (5 ml/kg; 0.5 mg GABA/kg) significantly (P

Josef Sýkora - One of the best experts on this subject based on the ideXlab platform.

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    Goals:To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children.Background:Lactobacillus species possess in vitro activity aga

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    GOALS: To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children. BACKGROUND: Lactobacillus species possess in vitro activity against H. pylori. There are no consistent data on the impact of eradication therapy supplemented with probiotics on H. pylori cure rates in childhood in vivo. STUDY: Multicenter, prospective, randomized, double-blind controlled study. Eighty-six symptomatic H. pylori-positive children were randomized either to receive the control treatment of omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days or the test treatment of omeprazole, amoxicillin, and clarithromycin for 7 days supplemented with Fermented Milk (Actimel) containing L. casei DN-114 001 (OAC-LC), for 14 days. H. pylori status was assessed at 4 weeks following therapy using two noninvasive tests. RESULTS: Intention-to-treat (ITT) based eradication rates for the OAC-LC group were 84.6% (95% CI, 71.2%-95.5%), and 91.6% (95% CI, 76.9%-98.2%) by per-protocol (PP) analysis. Eradication in the OAC group was 57.5% (95% CI, 42.2%-72.3%) in the ITT set and 61.3% (95% CI, 44.4%-75.0%) in the PP group. Eradication success was higher in the OAC-LC group compared with the OAC group in both ITT (P=0.0045) and PP analysis (P=0.0019). Primary resistance for clarithromycin could be determined in 21.2%. Side effects were infrequent. Drug compliance was good throughout the study. CONCLUSION: Supplementation with Fermented Milk, containing live special probiotic L. casei DN-114 001, confers an enhanced therapeutic benefit on H. pylori eradication in children with gastritis on triple therapy.

Konrad Siala - One of the best experts on this subject based on the ideXlab platform.

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    Goals:To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children.Background:Lactobacillus species possess in vitro activity aga

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    GOALS: To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children. BACKGROUND: Lactobacillus species possess in vitro activity against H. pylori. There are no consistent data on the impact of eradication therapy supplemented with probiotics on H. pylori cure rates in childhood in vivo. STUDY: Multicenter, prospective, randomized, double-blind controlled study. Eighty-six symptomatic H. pylori-positive children were randomized either to receive the control treatment of omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days or the test treatment of omeprazole, amoxicillin, and clarithromycin for 7 days supplemented with Fermented Milk (Actimel) containing L. casei DN-114 001 (OAC-LC), for 14 days. H. pylori status was assessed at 4 weeks following therapy using two noninvasive tests. RESULTS: Intention-to-treat (ITT) based eradication rates for the OAC-LC group were 84.6% (95% CI, 71.2%-95.5%), and 91.6% (95% CI, 76.9%-98.2%) by per-protocol (PP) analysis. Eradication in the OAC group was 57.5% (95% CI, 42.2%-72.3%) in the ITT set and 61.3% (95% CI, 44.4%-75.0%) in the PP group. Eradication success was higher in the OAC-LC group compared with the OAC group in both ITT (P=0.0045) and PP analysis (P=0.0019). Primary resistance for clarithromycin could be determined in 21.2%. Side effects were infrequent. Drug compliance was good throughout the study. CONCLUSION: Supplementation with Fermented Milk, containing live special probiotic L. casei DN-114 001, confers an enhanced therapeutic benefit on H. pylori eradication in children with gastritis on triple therapy.

J Varvarovska - One of the best experts on this subject based on the ideXlab platform.

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    Goals:To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children.Background:Lactobacillus species possess in vitro activity aga

  • effects of a specially designed Fermented Milk Product containing probiotic lactobacillus casei dn 114 001 and the eradication of h pylori in children a prospective randomized double blind study
    Journal of Clinical Gastroenterology, 2005
    Co-Authors: Josef Sýkora, K Valeckova, J Amlerova, Konrad Siala, P Dedek, S Watkins, J Varvarovska, F Stozický, P Pazdiora, Jan Schwarz
    Abstract:

    GOALS: To determine the efficacy of triple therapy supplemented with a specially designed Fermented Milk Product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children. BACKGROUND: Lactobacillus species possess in vitro activity against H. pylori. There are no consistent data on the impact of eradication therapy supplemented with probiotics on H. pylori cure rates in childhood in vivo. STUDY: Multicenter, prospective, randomized, double-blind controlled study. Eighty-six symptomatic H. pylori-positive children were randomized either to receive the control treatment of omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days or the test treatment of omeprazole, amoxicillin, and clarithromycin for 7 days supplemented with Fermented Milk (Actimel) containing L. casei DN-114 001 (OAC-LC), for 14 days. H. pylori status was assessed at 4 weeks following therapy using two noninvasive tests. RESULTS: Intention-to-treat (ITT) based eradication rates for the OAC-LC group were 84.6% (95% CI, 71.2%-95.5%), and 91.6% (95% CI, 76.9%-98.2%) by per-protocol (PP) analysis. Eradication in the OAC group was 57.5% (95% CI, 42.2%-72.3%) in the ITT set and 61.3% (95% CI, 44.4%-75.0%) in the PP group. Eradication success was higher in the OAC-LC group compared with the OAC group in both ITT (P=0.0045) and PP analysis (P=0.0019). Primary resistance for clarithromycin could be determined in 21.2%. Side effects were infrequent. Drug compliance was good throughout the study. CONCLUSION: Supplementation with Fermented Milk, containing live special probiotic L. casei DN-114 001, confers an enhanced therapeutic benefit on H. pylori eradication in children with gastritis on triple therapy.